InnoCare Pharma Ltd. (9969) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

9969 Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

InnoCare

Pharma Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

9969 Stock 12 Month Forecast

Average Price Target

HK$21.80

▲(63.91% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for InnoCare Pharma Ltd. in the last 3 months. The average price target is HK$21.80 with a high forecast of HK$26.70 and a low forecast of HK$19.00. The average price target represents a 63.91% change from the last price of HK$13.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","9":"HK$9","15":"HK$15","21":"HK$21","27":"HK$27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$26.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$21.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9,15,21,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.25,15.207692307692307,16.165384615384614,17.123076923076923,18.08076923076923,19.03846153846154,19.996153846153845,20.953846153846154,21.911538461538463,22.869230769230768,23.826923076923077,24.784615384615385,25.74230769230769,{"y":26.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.25,14.830769230769231,15.411538461538461,15.992307692307692,16.573076923076922,17.153846153846153,17.734615384615385,18.315384615384616,18.896153846153847,19.47692307692308,20.057692307692307,20.638461538461538,21.21923076923077,{"y":21.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.25,14.615384615384615,14.98076923076923,15.346153846153847,15.711538461538462,16.076923076923077,16.442307692307693,16.807692307692307,17.173076923076923,17.53846153846154,17.903846153846153,18.26923076923077,18.634615384615383,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.08,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$26.70

Average Price TargetHK$21.80

Lowest Price TargetHK$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chen Chen

UBS

HK$23.6

Buy

77.44%

Upside

Reiterated

12/14/25

InnoCare Pharma Ltd. (9969) Gets a Buy from UBS

Jack Lin

Morgan Stanley

HK$19.6

Hold

47.37%

Upside

Reiterated

11/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (NASDAQ: DRMA), CSPC Pharmaceutical Group (Other OTC: CHJTF) and InnoCare Pharma Ltd. (HKEX: HK:9969)

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$19

Buy

42.86%

Upside

Reiterated

11/17/25

SWS Res Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)

Unknown Analyst

Shenwan Hongyuan

Not Ranked

Shenwan Hongyuan

HK$19

Buy

42.86%

Upside

Reiterated

11/17/25

Shenwan Hongyuan Sticks to Their Buy Rating for InnoCare Pharma Ltd. (9969)

Ziyi Chen

Goldman Sachs

HK$20.59→HK$22.89

Buy

72.11%

Upside

Reiterated

10/09/25

InnoCare Pharma Ltd. (9969) Receives a Buy from Goldman Sachs

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$26.7

Buy

100.75%

Upside

Reiterated

09/23/25

Unknown Analyst

SPDB

Not Ranked

SPDB

HK$21

Buy

57.89%

Upside

Reiterated

08/26/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$12.41

Buy

-6.69%

Downside

Reiterated

05/21/25

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$11.8

Buy

-11.28%

Downside

Reiterated

05/15/25

Jill Wu

CMB International Securities

HK$11.95

Buy

-10.15%

Downside

Reiterated

05/15/25

InnoCare Pharma Ltd.: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chen Chen

UBS

HK$23.6

Buy

77.44%

Upside

Reiterated

12/14/25

InnoCare Pharma Ltd. (9969) Gets a Buy from UBS

Jack Lin

Morgan Stanley

HK$19.6

Hold

47.37%

Upside

Reiterated

11/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (NASDAQ: DRMA), CSPC Pharmaceutical Group (Other OTC: CHJTF) and InnoCare Pharma Ltd. (HKEX: HK:9969)

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$19

Buy

42.86%

Upside

Reiterated

11/17/25

SWS Res Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)

Unknown Analyst

Shenwan Hongyuan

Not Ranked

Shenwan Hongyuan

HK$19

Buy

42.86%

Upside

Reiterated

11/17/25

Shenwan Hongyuan Sticks to Their Buy Rating for InnoCare Pharma Ltd. (9969)

Ziyi Chen

Goldman Sachs

HK$20.59→HK$22.89

Buy

72.11%

Upside

Reiterated

10/09/25

InnoCare Pharma Ltd. (9969) Receives a Buy from Goldman Sachs

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$26.7

Buy

100.75%

Upside

Reiterated

09/23/25

Unknown Analyst

SPDB

Not Ranked

SPDB

HK$21

Buy

57.89%

Upside

Reiterated

08/26/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$12.41

Buy

-6.69%

Downside

Reiterated

05/21/25

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$11.8

Buy

-11.28%

Downside

Reiterated

05/15/25

Jill Wu

CMB International Securities

HK$11.95

Buy

-10.15%

Downside

Reiterated

05/15/25

InnoCare Pharma Ltd.: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering InnoCare Pharma Ltd.

1 Month

xxx

Success Rate

3/5 ratings generated profit

Average Return

+16.98%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +16.98% per trade.

3 Months

xxx

Success Rate

2/5 ratings generated profit

Average Return

+11.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +11.40% per trade.

1 Year

Jill WuCMB International Securities

Success Rate

2/3 ratings generated profit

Average Return

+48.87%

reiterated a buy rating 7 months ago

Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +48.87% per trade.

2 Years

xxx

Success Rate

2/5 ratings generated profit

Average Return

+21.10%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +21.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9969 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 9969 has received 6 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 9969 average Analyst price target in the past 3 months is 21.80.

Each month's total comprises the sum of three months' worth of ratings.

9969 Financial Forecast

9969 Earnings Forecast

Next quarter’s earnings estimate for 9969 is HK$0.35 with a range of HK$0.35 to HK$0.35. The previous quarter’s EPS was -HK$0.02. 9969 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 9969 has Performed in-line its overall industry.

9969 Sales Forecast

Next quarter’s sales forecast for 9969 is HK$1.87B with a range of HK$1.87B to HK$1.87B. The previous quarter’s sales results were HK$419.47M. 9969 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 9969 has Performed in-line its overall industry.

9969 Stock Forecast FAQ

What is HK:9969’s average 12-month price target, according to analysts?

Based on analyst ratings, InnoCare Pharma Ltd.’s 12-month average price target is 21.80.

What is HK:9969’s upside potential, based on the analysts’ average price target?

InnoCare Pharma Ltd. has 63.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is InnoCare Pharma Ltd. a Buy, Sell or Hold?

InnoCare Pharma Ltd. has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is InnoCare Pharma Ltd.’s share price target?

The average share price target for InnoCare Pharma Ltd. is 21.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$26.70 ,and the lowest forecast is HK$19.00. The average share price target represents 63.91% Increase from the current price of HK$13.3.

What do analysts say about InnoCare Pharma Ltd.?

InnoCare Pharma Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of InnoCare Pharma Ltd.?

To buy shares of HK:9969, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

InnoCare Pharma Ltd. (9969) Stock Forecast & Price Target

9969 Analyst Ratings

9969 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering InnoCare Pharma Ltd.

9969 Analyst Recommendation Trends

9969 Financial Forecast

9969 Earnings Forecast

9969 Sales Forecast

9969 Stock Forecast FAQ

Detailed List of Analyst Forecasts